Treatment of uterine fibroids: current findings with gonadotropin-releasing hormone agonists

Am J Obstet Gynecol. 1992 Feb;166(2):746-51. doi: 10.1016/0002-9378(92)91707-h.


The gonadotropin-releasing hormone agonists have potential benefit as presurgical adjuncts in the management of uterine leiomyomas or fibroids. Uterine fibroids contain estrogen receptors and are responsive to therapeutic hormonal manipulation; gonadotropin-releasing hormone agonists are effective by inducing a state of hypoestrogenism. Clinical trials with gonadotropin-releasing hormone agonists consistently have demonstrated efficacy for decreasing both myoma size and uterine volume. The advantages of the preoperative use of gonadotropin-releasing hormone agonists include a reduction in uterine and myoma size and vascularity and potentially improved operative technique and uterine cavity integrity. Ongoing clinical trials will be needed to confirm the role of gonadotropin-releasing hormone agonists in the treatment of uterine fibroids.

Publication types

  • Review

MeSH terms

  • Analysis of Variance
  • Combined Modality Therapy
  • Female
  • Gonadotropin-Releasing Hormone / adverse effects
  • Gonadotropin-Releasing Hormone / analogs & derivatives
  • Gonadotropin-Releasing Hormone / therapeutic use*
  • Humans
  • Leiomyoma / blood supply
  • Leiomyoma / drug therapy*
  • Leiomyoma / surgery
  • Leuprolide / therapeutic use
  • Nafarelin
  • Remission Induction
  • Uterine Neoplasms / blood supply
  • Uterine Neoplasms / drug therapy*
  • Uterine Neoplasms / surgery
  • Uterus / drug effects


  • Nafarelin
  • Gonadotropin-Releasing Hormone
  • Leuprolide